The Immunomodulation Unit at the biomedical research centre Navarrabiomed, with the cooperation of the Medical Oncology Service from the Hospital Complex of Navarre (HCN), has identified molecular properties in the immune system of lung cancer patients involved in clinical responses to immunotherapy based on PD-L1/PD-1 inhibitors. The study, published in EMBO Molecular Medicine, was made possible by the support of Spanish association against cancer and the Carlos III Institute.
On 16 May, Navarrabiomed held a workshop on Molecular Biology, Cancer and Bioinformatics in the context of ONCONET SUDOE, a transnational European project co-financed by the INTERREG SUDOE Programme 2014-2020. The project is aimed at connecting researchers, healthcare providers, biobanks and companies, for the establishment of long-term relationships that foster innovation in oncology.
A total of 90 experts from 32 organisations participated in the event’s three sessions and two panels, focusing on the molecular basis of cancer, liquid biopsy, genomics and cancer bioinformatics.
Scientists from Navarrabiomed - a joint research center between Public University of Navarra and the Government of Navarra - have characterized the sensory system that bacteria use to grow in the human body and cause an infection.
This work which has been published in the scientific journal Nature Communications and has been funded by the Spanish Ministry of Economy, Industry and Competitiveness, allows to better understand how bacteria adapt to different environmental conditions and will enable the development of more specific and effective antibiotics.
Refbio II, the second phase of the Pyrenean Biomedical Trans border Research Network, supports seven research projects in total, four of which have the participation of Navarrese researchers from the Hospital Complex of Navarra (CHN) and Navarrabiomed. The projects were selected from 15 proposals submitted to the internal call of the Network whose total funding exceeds 400,000 euros.